Fresenius Signs Exclusive Biosimilar Development Deal With WuXi
The agreement gives Fresenius exclusive options for up to 37 biosimilar candidates targeting original products with a combined market value exceeding 370 billion euros. Fresenius retains full economic rights and strategic control under a fee-for-service model.
Fresenius has entered into an exclusive development agreement with WuXi Biologics to significantly expand its biosimilars pipeline. The partnership grants Fresenius exclusive options for up to 37 potential biosimilar candidates, targeting original products with a combined market value exceeding 370 billion euros. Unlike traditional licensing models, Fresenius will utilize a 'fee-for-service' approach, allowing the company to retain full economic rights and strategic control over the development and marketing of these products. CEO Michael Sen stated that the agreement is designed to scale the biopharma business and provide a foundation for growth well beyond 2030.
Alongside this announcement, the company confirmed its financial guidance for the current year, including an expected 10 to 15 percent increase in core earnings per share.